[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献_第8页

[Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)]. [基于京都血液学临床研究组（KOTOSG） 15年临床研究的弥漫性大b细胞淋巴瘤的临床问题和观点]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.153

Eri Kawata, Takahiro Fujino, Tsutomu Kobayashi, Haruya Okamoto, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Daichi Nishiyama, Yuri Kamitsuji, Shin-Ichi Fuchida, Mitsushige Nakao, Ryoichi Takahashi, Hiroto Kaneko, Hitoji Uchiyama, Koichi Hirakawa, Nobuhiko Uoshima, Junya Kuroda

{"title":"[Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)].","authors":"Eri Kawata, Takahiro Fujino, Tsutomu Kobayashi, Haruya Okamoto, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Daichi Nishiyama, Yuri Kamitsuji, Shin-Ichi Fuchida, Mitsushige Nakao, Ryoichi Takahashi, Hiroto Kaneko, Hitoji Uchiyama, Koichi Hirakawa, Nobuhiko Uoshima, Junya Kuroda","doi":"10.11406/rinketsu.66.153","DOIUrl":"10.11406/rinketsu.66.153","url":null,"abstract":"Since 2010, the Kyoto Hematology Clinical Research Group (KOTOSG), a multicenter clinical research group, has dedicated itself to clinical studies on hematological diseases based on daily clinical practice. These studies have provided information about patient characteristics, treatment outcomes, and adverse events in actual clinical practice, and have improved the standard of local medical care by uncovering differences between facilities. In addition, study results have clarified ongoing problems that pose the next challenges for both clinical and basic research. The disease most widely studied was diffuse large B-cell lymphoma (DLBCL). Studies related to DLBCL covered various topics: (1) development of a new prognostic index that can identify highly refractory patients with high accuracy, such as the Kyoto Prognostic Index (KPI) for newly diagnosed DLBCL and KPI-R for relapsed/refractory DLBCL, (2) identification of cytogenetic and clinicopathological characteristics of patients with a poor prognosis, and (3) issues with second cancers after successful treatment. In this article, we review the results of clinical studies on DLBCL by KOTOSG, comparing them with those of past clinical studies in DLBCL, mainly those conducted in Japan. We hope these studies will help to advance the field of clinical hematology.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 3","pages":"153-164"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.405

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.526

引用次数: 0

[Development of a method for mass production of functional neutrophils derived from human induced pluripotent stem cells]. [从人类诱导多能干细胞中大量生产功能性中性粒细胞的方法的发展]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.517

Toshiya Hino, Mineo Kurokawa

引用次数: 0

[Renal impairment associated with myeloproliferative neoplasms]. [与骨髓增生性肿瘤相关的肾脏损害]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.407

Yasutaka Fukuda

引用次数: 0

[Current state of CAR-T cell therapy for relapsed/refractory ALL in children and young adults]. CAR-T细胞治疗儿童和年轻人复发/难治性ALL的现状。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.673

Hidefumi Hiramatsu

引用次数: 0

[Treatment of adult T-cell leukemia/lymphoma: past, present, and future]. 成人t细胞白血病/淋巴瘤的治疗：过去、现在和未来。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.781

Kenji Ishitsuka

{"title":"[Treatment of adult T-cell leukemia/lymphoma: past, present, and future].","authors":"Kenji Ishitsuka","doi":"10.11406/rinketsu.66.781","DOIUrl":"https://doi.org/10.11406/rinketsu.66.781","url":null,"abstract":"Adult T-cell leukemia/lymphoma (ATL) is a T-cell malignancy caused by human T-cell leukemia virus type I (HTLV-1). Treatment strategies have been established by classification of ATL as aggressive (acute, lymphoma, and chronic ATL with any unfavorable prognostic factors) or indolent (smoldering and chronic ATL without any unfavorable prognostic factors). The standard of care (SOC) for aggressive ATL has been dose-intensified multi-agent chemotherapy. The introduction of allogeneic hematopoietic stem cell transplantation was a treatment breakthrough for patients around 70 years or younger. Moreover, five novel drugs have been approved and entered clinical use in Japan since 2012. Outside Japan, the combination of interferon-alfa and zidovudine (IFN/AZT) has been considered a SOC, despite a lack of well-designed clinical trials. The SOC for indolent ATL is watchful waiting in Japan, but also includes IFN/AZT for symptomatic cases outside Japan. In the absence of robust evidence for either approach, a phase 3 trial to validate the benefit of IFN/AZT is ongoing in Japan, and the results are due to be published in late 2025. Looking to the future, there is an obvious decline in HTLV-1 infected individuals in the younger population in Japan, and the success of a nationwide program preventing mother-to-child infection by recommending avoidance of breastfeeding should further contribute to this trend.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 8","pages":"781-788"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Recent advances in research of cure of HIV infection]. [HIV感染治疗研究进展]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.796

Kotaro Shirakawa

{"title":"[Recent advances in research of cure of HIV infection].","authors":"Kotaro Shirakawa","doi":"10.11406/rinketsu.66.796","DOIUrl":"10.11406/rinketsu.66.796","url":null,"abstract":"Antiretroviral therapy (ART) is a well-established treatment for HIV infection that suppresses viral replication by inhibiting viral enzymatic activity, thereby preventing progression to immunodeficiency. However, discontinuation of ART typically leads to rapid viral rebound within weeks, due to the reactivation of latent HIV from long-lived reservoirs such as resting CD4+ T cells. Eradication of these latent reservoirs is essential to achieve a cure for HIV. In 2009, the first case of HIV cure was reported: an individual with HIV and acute leukemia received an allogeneic hematopoietic stem cell transplant (HSCT) from a donor homozygous for the CCR5Δ32 mutation, which results in the absence of the HIV coreceptor CCR5. After ART interruption, the patient maintained undetectable plasma viremia without viral rebound. Since then, a total of nine cases with similar post-transplant virological remission have been documented globally. This review summarizes the clinical characteristics of reported cases of HIV cure, outlines the shock-and-kill strategy targeting latent HIV reservoirs, and discusses the current progress in the development of therapies to cure HIV using latency-reversing agents (LRAs).","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 8","pages":"796-805"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Multimodal functions of HTLV-1 in oncogenesis of adult T-cell leukemia-lymphoma]. [HTLV-1在成人t细胞白血病-淋巴瘤肿瘤发生中的多模式功能]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.773

Jun-Ichirou Yasunaga

{"title":"[Multimodal functions of HTLV-1 in oncogenesis of adult T-cell leukemia-lymphoma].","authors":"Jun-Ichirou Yasunaga","doi":"10.11406/rinketsu.66.773","DOIUrl":"10.11406/rinketsu.66.773","url":null,"abstract":"Adult T-cell leukemia-lymphoma (ATL) is a malignancy of peripheral CD4+ T cells induced by human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 encodes two oncogenic viral factors, Tax and HTLV-1 bZIP factor (HBZ) in the sense and antisense strands of the provirus respectively. Both Tax and HBZ dysregulate the expression and activities of a large number of host genes and cellular signaling pathways via their multimodal functions. Tax is a potent transactivator of viral replication and various cancer-related genes in HTLV-1-infected cells; however, Tax expression is generally suppressed in ATL cells owing to its high immunogenicity. Previously, we reported that Tax is transiently expressed in a small subpopulation of ATL cells, leading to drastic changes in the host transcriptional profile. In contrast, HBZ is conserved and expressed in all ATL patients. The HBZ gene is thought to be essential in the pathogenesis of HTLV-1. It is unique in that its transcript not only encodes HBZ protein but also acts in a similar way to long non-coding RNAs. Among the functions of HBZ, activation of the TGF-β/Smad pathway is critical for proliferation of ATL cells. These multimodal actions of Tax and HBZ genes are thought to be critical for ATL leukemogenesis.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 8","pages":"773-780"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Aplastic anemia in children: recent advances in diagnosis and treatment]. 儿童再生障碍性贫血：诊断和治疗的最新进展。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1165

Nao Yoshida

引用次数: 0